55265-53-7

Usage

Uses

Used in Rubber Industry:
2,2,3,3-Tetramethylcyclopropanecarboxamide is used as an antioxidant for enhancing the durability and performance of rubber products. It helps in preventing degradation and discoloration of rubber, thereby extending the service life of rubber goods.
Used in Plastics and Elastomers Industry:
In the plastics and elastomers industry, 2,2,3,3-Tetramethylcyclopropanecarboxamide serves as a stabilizer, ensuring the maintenance of the material's properties under various environmental conditions. Its high thermal stability makes it an ideal choice for applications where plastics and elastomers are exposed to high temperatures.
Used in Pharmaceutical Production:
2,2,3,3-Tetramethylcyclopropanecarboxamide is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
Similarly, in the agrochemical sector, 2,2,3,3-Tetramethylcyclopropanecarboxamide is employed as an intermediate for the production of various agrochemicals, including pesticides and herbicides, to improve their effectiveness and stability in agricultural settings.

InChI:InChI=1/C8H15NO/c1-7(2)5(6(9)10)8(7,3)4/h5H,1-4H3,(H2,9,10)

Upstream product

• 24303-61-5 2,2,3,3-tetramethylcyclopropanecarbonyl chloride 
• 15641-58-4 2,2,3,3-tetramethylcyclopropane-1-carboxylic acid 

Downstream Products

• 67358-15-0 2,2,3,3-tetramethylcyclopropanemethylamine 

Relevant academic research and scientific papers

Facile synthesis of amide and amine derivatives of 2,2,3,3- tetramethylcyclopropanecarboxylic acid

An efficient one-pot procedure for the synthesis of amide derivatives of 2,2,3,3-tetramethylpropanecarboxylic acid (TMCA) that involves the treating of TMCA in A/,A/-dimethylacetamide (DMAC) with thionyl chloride and stoichiometric amounts of reactant ami

Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases

An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.

Derivatives of tetramethylcyclopropane

The present invention relates to derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid (TMCA) of general formula (I), STR1 wherein R is lower alkyl group (C1 -C6), an aryl group, an aralkyl group or an amide of general formula (II), STR2 where R1 and R2 are the same or different and may be hydrogen, a alkyl group (C1 -C6), an aryl group or an aralkyl group, and n=0-3, to their racemic mixtures and the D and L enantiomers. The invention also relates to processes for the preparation of said compounds and for pharmaceutical preparations comprising the same. The new compounds show improved activity against epilepsy.

Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide

Purpose. The described structure pharmacokinetic pharmacodynamic relationships (SPPR) study explored the utilization of tetramethylcyclopropane analogues of valpromide (VPD, or tetramethylcyclopropane carboxamide derivatives of valproic acid (VPA) as new antiepileptics. Methods. The study was carried out by investigating the pharmacokinetics in dogs and pharmacodynamics (anticonvulsant activity and neurotoxicity) of the following three cyclopropane analogues of VPD: 2,2,3,3-tetramethylcyclopropane carboxamide (TMCD), N-methyl TMCD (M-TMCD) and N-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-glycinamide (TMC-GLD). Results. The three investigated compounds showed a good anticonvulsant profile in mice and rats due to the fact that they were metabolically stable VPD analogues which were not biotransformed to their non-active acid, 2,2,3,3-tetramethylcyclopropane carboxylic acid (TMCA). M-TMCD was metabolized to TMCD and TMC-GLD underwent partial biotransformation to its glycine analogue N-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-glycine (TMC-GLN). Unlike TMC-GLN, the above mentioned amides had low clearance and a relatively long half life. Conclusions. In contrast-to VPD which is biotransformed to VPA, the aforementioned cyclopropane derivatives were found. to be stable to amide-acid biotransformation. TMCD and M-TMCD show that cyclic analogues of VPD, like its aliphatic isomers, must have either two substitutions at the p position to the carbonyl, such as in the case of TMCD, or a substitution in the or and in the β positions like in the VPD isomer, valnoctamide (VCD). This paper discusses the antiepileptic potential of tetramethylcyclopropane analogues of VPD which are in animal models more potent than VPA and may be non-teratogenic and non-hepatotoxic.

Branched amides of L-aspartyl-D-amino acid dipeptides

Amides of L-aspartyl-D-amino acid dipeptides of the formula STR1 and physiologically acceptable cationic and acid addition salts thereof wherein Ra is CH2 OH or CH2 OCH3 ; R is a branched member selected from the group consisting of fenchyl, diisopropylcarbinyl, d-methyl-t-butylcarbinyl, d-ethyl-t-butylcarbinyl, di-t-butylcarbinyl, 2-methylthio-2,4-dimethylpentan-3-yl, STR2 where at least one of R3, R4, R5, R6 is alkyl having from one to four carbon atoms and the remainder are hydrogen or alkyl having from one to four carbon atoms, X is O, S, SO, SO2, C=O or CHOH; m is zero or 1-4, n and p are each zero, 1, 2 or 3 where the sum of n+p is not greater than 3 and the sum of the carbon atoms in R3, R4, R5 and R6 is not greater than six, and when both of R3 and R4 or R5 and R6 are alkyl they are methyl or ethyl, STR3 where one of R7, R8, R9 is alkyl having from one to four carbon atoms and the remainder are hydrogen or alkyl having from one to four carbon atoms and the sum of the carbon atoms in R7, R8 and R9 is not greater than six, m and q are the same or different and each have the values previously defined for m; STR4 where each of R12 and R13 are methyl or ethyl, or R12 is hydrogen and R13 is alkyl having from one to four carbon atoms, Z is O or NH and t is 1 or 2, STR5 where W is 1-4, R14 and R16 are each alkyl having from one to four carbon atoms, R15 is H, OH, methyl or ethyl and the sum of the carbon atoms in R14, R15 and R16 is not greater than six and when both of R14 and R15 are alkyl they are methyl or ethyl, and STR6 where R17 and R19 are alkyl having from one to four carbon atoms, R18 and R20 are H or alkyl having one to two carbon atoms, A is OH and B is H, OH or CH3 and taken together A and B are STR7 where the sum of the carbon atoms in R17, R18, R19 and R20 is not greater than six and when both of R17 and R18 or R19 and R20 are alkyl they are methyl or ethyl; said amides are potent sweeteners having advantages over the prior art, edible compositions containing them, methods for their use in edible compositions and novel amide intermediates useful in their production.